Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [14C]-esreboxetine
esreboxetine · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | EXPERIMENTAL | - |
| One | EXPERIMENTAL | - |
| Two | PLACEBO_COMPARATOR | - |
| Three | ACTIVE_COMPARATOR | Administration of a single oral dse of 400mg moxifloxacin |
| Name | Type | Description |
|---|---|---|
| Esreboxetine | DRUG | Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing |
| placebo | DRUG | Once daily administration of placebo for 9 days. Placebo will be administered double blind |
| moxifloxacin | DRUG | Once daily administration of placebo for 8 days followed by open label single oral dose of 400mg moxifloxacin on day 9 |
Inclusion Criteria: * Subjects who have a recognised diagnosis of fibromyalgia, with defined minimum pain criteria. Control subjects must not have a fibromyalgia diagnosis or symptoms and must match fibromyalgia subjects for age, length of education and gender Exclusion Criteria: * Other confound...
Top 1 of 2 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Axsome Therapeutics, Inc. | AXSM | 2 | PHASE3 | AXS-14 |
Esreboxetine has been studied as a treatment for fibromyalgia, a chronic condition characterized by widespread musculoskeletal pain. It was developed by Pfizer, Inc. and reached Phase 2 clinical development for this indication. It is an investigational drug and is not approved for any use.
Esreboxetine targets SLC6A2, also known as the norepinephrine transporter. It acts as an inhibitor of this transporter. By inhibiting SLC6A2, esreboxetine increases norepinephrine levels in the synaptic cleft, which may help modulate pain signaling in fibromyalgia.
Esreboxetine is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. Pfizer conducted the clinical trials for esreboxetine in fibromyalgia.
Esreboxetine is in Phase 2 clinical development for fibromyalgia. It is an investigational small molecule and has not been approved by the FDA or any regulatory agency for any indication. The completed trials include one Phase 1 and one Phase 2 study.
Esreboxetine has been evaluated in two completed clinical trials. NCT00809289 was a Phase 1 thorough QT study in 40 healthy volunteers in Belgium. NCT00752505 was a Phase 2 study assessing esreboxetine's effects on concentration, memory, decision making, and problem solving in 89 patients with fibromyalgia in the United States.
Yes, [14C]-esreboxetine is an alternative name for esreboxetine. The [14C] designation indicates a carbon-14 radiolabeled form of the same molecule, often used in clinical pharmacology studies to track the drug's absorption, distribution, metabolism, and excretion.